Atlas Trials

Infections, Rotavirus

58 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Infections, Rotavirus

RecordFirmDate
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (NCT03954743)GlaxoSmithKline2019-07-19
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (NCT02914184)GlaxoSmithKline2016-10-27
Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007 (NCT01563146)GlaxoSmithKline2016-02-01
Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis (NCT01978223)GlaxoSmithKline2014-12-01
Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™ (NCT02153333)GlaxoSmithKline2014-02-01
Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in Belgium (NCT01592838)GlaxoSmithKline2013-12-01
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination (NCT01915888)GlaxoSmithKline2013-08-01
A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and Latvia (NCT01733849)GlaxoSmithKline2012-12-01
Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis (NCT01733862)GlaxoSmithKline2012-11-27
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination (NCT01682005)GlaxoSmithKline2012-08-01
Special Drug Use Investigation for ROTARIX® (NCT01636739)GlaxoSmithKline2012-07-01
Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™ (NCT01435967)GlaxoSmithKline2011-09-01
Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium (NCT01339221)GlaxoSmithKline2011-03-01
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth. (NCT01198769)GlaxoSmithKline2010-11-11
Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants (NCT01171963)GlaxoSmithKline2010-08-29
Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants (NCT01107587)GlaxoSmithKline2010-04-13
Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine (NCT01110044)GlaxoSmithKline2010-04-01
Study to Evaluate the Safety of Rotarix™ in Chinese Children (NCT01086436)GlaxoSmithKline2010-03-13
Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants (NCT00969228)GlaxoSmithKline2009-08-25
Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants (NCT00938327)GlaxoSmithKline2009-08-03
Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States (NCT00875641)GlaxoSmithKline2009-04-20
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants (NCT00779779)GlaxoSmithKline2008-11-22
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants (NCT00750893)GlaxoSmithKline2008-09-02
Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama (NCT00653198)GlaxoSmithKline2008-03-19
Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children (NCT01177826)GlaxoSmithKline2008-02-23
Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in Children < 5 Years of Age in Romania (NCT01253967)GlaxoSmithKline2008-02-01
Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden (NCT00489567)GlaxoSmithKline2007-10-01
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age (NCT00533507)GlaxoSmithKline2007-09-18
Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants (NCT00480324)GlaxoSmithKline2007-06-19
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. (NCT00432380)GlaxoSmithKline2007-03-09
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine. (NCT00420316)GlaxoSmithKline2007-02-12
To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants (NCT00420745)GlaxoSmithKline2007-01-25
A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family. (NCT00396630)GlaxoSmithKline2007-01-23
Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210) (NCT00329745)GlaxoSmithKline2007-01-01
A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). (NCT00382772)GlaxoSmithKline2006-11-01
Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines (NCT00370318)GlaxoSmithKline2006-09-01
To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) (NCT00345956)GlaxoSmithKline2006-09-01
To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) (NCT00363545)GlaxoSmithKline2006-09-01
Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA (NCT00334607)GlaxoSmithKline2006-06-01
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India (NCT00289172)GlaxoSmithKline2006-02-10
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants (NCT00241644)GlaxoSmithKline2005-10-01
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis (NCT00137930)GlaxoSmithKline2005-08-01
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis (NCT00134732)GlaxoSmithKline2005-07-01
A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh (NCT00139334)GlaxoSmithKline2005-06-01
A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa (NCT00263666)GlaxoSmithKline2005-03-16
To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines (NCT00140686)GlaxoSmithKline2004-09-01
A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants (NCT00197210)GlaxoSmithKline2003-12-01
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants (NCT00139347)GlaxoSmithKline2003-12-01
Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa (NCT00383903)GlaxoSmithKline2003-09-01
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants. (NCT00140673)GlaxoSmithKline2003-08-05
Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine (NCT00757770)GlaxoSmithKline2003-08-01
Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months (NCT00385320)GlaxoSmithKline2001-05-31
Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. (NCT00729001)GlaxoSmithKline2000-11-01
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants (NCT00425737)GlaxoSmithKline2000-08-01

Track Infections, Rotavirus automatically

Every clearance here is in the API, with alerts when new ones post.